Endurance Wealth Management Inc. Sells 3,410 Shares of Pfizer Inc. (PFE)

Endurance Wealth Management Inc. lowered its position in Pfizer Inc. (NYSE:PFE) by 1.9% during the second quarter, HoldingsChannel reports. The firm owned 175,223 shares of the biopharmaceutical company’s stock after selling 3,410 shares during the quarter. Pfizer makes up approximately 1.0% of Endurance Wealth Management Inc.’s holdings, making the stock its 28th largest holding. Endurance Wealth Management Inc.’s holdings in Pfizer were worth $6,357,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. HC Financial Advisors Inc. bought a new stake in shares of Pfizer during the 4th quarter worth about $2,685,000. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp boosted its stake in shares of Pfizer by 15.0% during the 4th quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 3,082,158 shares of the biopharmaceutical company’s stock worth $111,636,000 after acquiring an additional 402,638 shares in the last quarter. Dixon Hubard Feinour & Brown Inc. VA boosted its stake in shares of Pfizer by 1.5% during the 4th quarter. Dixon Hubard Feinour & Brown Inc. VA now owns 130,566 shares of the biopharmaceutical company’s stock worth $4,729,000 after acquiring an additional 1,925 shares in the last quarter. CNB Bank bought a new stake in shares of Pfizer during the 4th quarter worth about $2,057,000. Finally, Envestnet Asset Management Inc. boosted its stake in shares of Pfizer by 10.4% during the 4th quarter. Envestnet Asset Management Inc. now owns 1,086,886 shares of the biopharmaceutical company’s stock worth $39,367,000 after acquiring an additional 102,521 shares in the last quarter. Hedge funds and other institutional investors own 68.95% of the company’s stock.

NYSE PFE opened at $43.78 on Friday. Pfizer Inc. has a twelve month low of $33.20 and a twelve month high of $45.81. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.41. The stock has a market cap of $262.34 billion, a P/E ratio of 16.52, a price-to-earnings-growth ratio of 2.23 and a beta of 0.96.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, July 31st. The biopharmaceutical company reported $0.81 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.07. The business had revenue of $13.47 billion during the quarter, compared to analysts’ expectations of $13.30 billion. Pfizer had a return on equity of 25.35% and a net margin of 42.35%. The firm’s revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.67 EPS. As a group, analysts expect that Pfizer Inc. will post 2.99 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Monday, December 3rd. Shareholders of record on Friday, November 9th will be issued a $0.34 dividend. The ex-dividend date is Thursday, November 8th. This represents a $1.36 annualized dividend and a yield of 3.11%. Pfizer’s dividend payout ratio (DPR) is 51.32%.

Several analysts have recently issued reports on PFE shares. Cantor Fitzgerald set a $45.00 price target on Pfizer and gave the stock a “buy” rating in a research note on Thursday, October 4th. Morgan Stanley set a $45.00 price target on Pfizer and gave the stock a “buy” rating in a research note on Wednesday, August 29th. Credit Suisse Group upped their price target on Pfizer from $39.00 to $40.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 1st. Bank of America upped their price target on Pfizer from $42.00 to $43.00 and gave the stock a “buy” rating in a research note on Wednesday, August 1st. Finally, JPMorgan Chase & Co. reiterated a “$37.66” rating on shares of Pfizer in a research note on Wednesday, July 18th. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating and nine have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $42.40.

In other Pfizer news, insider Laurie J. Olson sold 10,214 shares of the company’s stock in a transaction that occurred on Monday, August 13th. The stock was sold at an average price of $41.00, for a total value of $418,774.00. Following the completion of the transaction, the insider now owns 72,672 shares of the company’s stock, valued at approximately $2,979,552. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Sally Susman sold 40,381 shares of the company’s stock in a transaction that occurred on Friday, July 20th. The shares were sold at an average price of $37.22, for a total value of $1,502,980.82. Following the completion of the transaction, the insider now directly owns 155,377 shares of the company’s stock, valued at approximately $5,783,131.94. The disclosure for this sale can be found here. In the last ninety days, insiders sold 761,230 shares of company stock valued at $29,054,690. Insiders own 0.06% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

See Also: Stock Split

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply